{"pmid":32209313,"title":"New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.","text":["New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.","Oral Oncol","Bennardo, Francesco","Buffone, Caterina","Giudice, Amerigo","32209313"],"journal":"Oral Oncol","authors":["Bennardo, Francesco","Buffone, Caterina","Giudice, Amerigo"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209313","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.oraloncology.2020.104659","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662444220186624001,"score":7.208847,"similar":[{"pmid":32187489,"title":"Audio Interview: New Research on Possible Treatments for Covid-19.","text":["Audio Interview: New Research on Possible Treatments for Covid-19.","N Engl J Med","Rubin, Eric J","Baden, Lindsey R","Morrissey, Stephen","32187489"],"journal":"N Engl J Med","authors":["Rubin, Eric J","Baden, Lindsey R","Morrissey, Stephen"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32187489","week":"202012|Mar 16 - Mar 22","doi":"10.1056/NEJMe2005759","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543490711552,"score":46.652},{"pmid":32208485,"title":"COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?","text":["COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?","JAMA","Patel, Ankit B","Verma, Ashish","32208485"],"journal":"JAMA","authors":["Patel, Ankit B","Verma, Ashish"],"date":"2020-03-26T11:00:00Z","year":2020,"_id":"32208485","week":"202013|Mar 23 - Mar 29","doi":"10.1001/jama.2020.4812","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1662334543437234176,"score":44.355972},{"pmid":32186711,"title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.","text":["Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.","Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections.","J Travel Med","Diaz, James H","32186711"],"abstract":["Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections."],"journal":"J Travel Med","authors":["Diaz, James H"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32186711","week":"202012|Mar 16 - Mar 22","doi":"10.1093/jtm/taaa041","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1662334543503294464,"score":40.108345}]}